help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2009.081142 on August 28, 2009

Published online before print August 28, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2009.081142v1
175/4/1353    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Muntean, A. G.
Right arrow Articles by Hess, J. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muntean, A. G.
Right arrow Articles by Hess, J. L.
(American Journal of Pathology. 2009;175:1353-1361.)
© 2009 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.081142

Biological Perspectives

Epigenetic Dysregulation in Cancer

Andrew G. Muntean and Jay L. Hess

From the Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan

Abstract

One of the great paradoxes in cellular differentiation is how cells with identical DNA sequences differentiate into so many different cell types. The mechanisms underlying this process involve epigenetic regulation mediated by alterations in DNA methylation, histone posttranslational modifications, and nucleosome remodeling. It is becoming increasingly clear that disruption of the "epigenome" as a result of alterations in epigenetic regulators is a fundamental mechanism in cancer. This has major implications for the future of both molecular diagnostics as well as cancer chemotherapy.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society for Investigative Pathology.